The challenge in the treatment of chronic retinal diseases is to deliver effective therapy to the target tissues in the back of the eye while limiting drug exposure in nontarget tissues. Intravitreal placement provides the most targeted drug delivery, but repeated penetration of the globe to deliver intravitreal therapy can pose safety risks. A more effective strategy for the treatment of chronic retinal diseases would be to combine intravitreal placement with sustained drug delivery. The dexamethasone intravitreal (DEX) implant is a biodegradable sustained-release intravitreal drug delivery system that is approved for the treatment of macular edema following branch or central retinal vein occlusion and for noninfectious uveitis affecting the posterior segment of the eye. A single DEX implant has been shown to provide clinical benefits for up to 6 months in eyes with retinal vein occlusion or intermediate or posterior uveitis.

Effect of Dexamethasone Intravitreal Implant on Patient-Reported Visual Functioning for the Treatment of Macular Edema Following Retinal Vein Occlusion

Effect of Dexamethasone Intravitreal Implant on Patient-Reported Visual Functioning for the Treatment of Macular Edema Following Retinal Vein Occlusion

Citations

Pharmacologic and clinical profile of dexamethasone intravitreal implant.

Related Papers (5)

12-Month Evaluation of Dexamethasone Intravitreal Implant in Patients With Macular Edema Due to Central Retinal Vein Occlusion

Intravitreal Dexamethasone Implant for Macular Edema in Branch Retinal Vein Occlusion According to Previous Responses to Bevacizumab

Exploring the Morphological and Functional Retinal Changes after Dexamethasone Intravitreal Implant (Ozurdex®) in Macular Edema due to Retinal Vein Occlusion

Intravitreal ranibizumab and/or dexamethasone implant for macular edema secondary to retinal vein occlusion.

Efficacy of dexamethasone intravitreal implant for refractory macular edema caused by retinal vein occlusion.